Quick Take
Vir Biotechnology (VIR) has filed to raise $150 million from the sale of its common stock, per an S-1/A registration statement.
The company is advancing an ambitious pipeline of drug and antibody treatments for immune system and infectious diseases.
VIR has produced intriguing early stage results in trials and has a significant commercial collaboration partner.
However, the proposed IPO valuation of $1.9 billion is well out of the typical range for biopharma IPOs, so I'll be watching this IPO from the sidelines.
Company & Technology
San Francisco, California-based Vir was